How to manage the transplant question in myelofibrosis

Abstract

Allogeneic stem cell transplantation remains the only curative therapy for myelofibrosis. Despite advances in transplant, the morbidity and the mortality of the procedure necessitate careful patient selection. In this manuscript, we describe the new prognostic scoring system to help select appropriate patients for transplant and less aggressive therapies. We explore the advances in non-transplant therapy, such as with investigational agents. We review the blossoming literature on results of myeloablative, reduced intensity and alternative donor transplantation. Finally, we make recommendations for which patients are most likely to benefit from transplantation.

Citation: Blood Cancer Journal (2012) 2, e59 doi:10.1038/bcj.2012.3 & 2012 Macmillan Publishers Limited All rights reserved 2044-5385/12

http://www.nature.com/

Web End =www.nature.com/bcj

HOW TO MANAGEy

How to manage the transplant question in myelobrosis

K Ballen

Allogeneic stem cell transplantation remains the only curative therapy for myelobrosis. Despite advances in transplant, the morbidity and the mortality of the procedure necessitate careful patient selection. In this manuscript, we describe the new prognostic scoring system to help select appropriate patients for transplant and less aggressive therapies. We explore the advances in non-transplant therapy, such as with investigational agents. We review the blossoming literature on results of myeloablative, reduced intensity and alternative donor transplantation. Finally, we make recommendations for which patients are most likely to benet from transplantation.

Blood Cancer Journal (2012) 2, e59; doi:http://dx.doi.org/10.1038/bcj.2012.3

Web End =10.1038/bcj.2012.3 ; published online 2 March 2012

Keywords: transplantation; myelobrosis; cord blood

DEFINITIONS OF MYELOFIBROSISMyelobrosis is now categorized based on the World Health

Organization criteria as a myeloproliferative neoplasm. Myelobrosis can be either primary or secondary, developing in patients with polycythemia vera or essential thrombocythemia.1 The median age is in the seventh decade and clinical features include anemia, splenomegaly and bone marrow brosis. About 70% of patients are positive for the Janus2 kinase (JAK2 kinase) mutation.2 Patients must fulll all the three major criteria (megakaryocyte proliferation, no evidence of other myeloid neoplasm, and JAK2/V617F or other clonal marker, or no reactive marrow brosis) and two minor criteria (leukoerythroblastosis, increased serum lactate dehydrogenase, anemia, palpable splenomegaly) to have primary myelobrosis.3

RISK STRATIFICATIONSeveral prognostic systems have been developed over the last 20 years to help determine which patients might benet from aggressive transplantation treatment. The older scoring system, such as the Lille or Dupriez, and the Cervantes score, focused primarily on blood counts as the major prognostic factors.4 A newer prognostic system is the International Prognostic Scoring System (IPSS), which includes age 465, hemoglobin level o10, white blood count 425 109/l, circulating blasts X1% and

presence of constitutional symptoms.5 The IPSS was further modied to the dynamic IPSS (DIPSS) for use at any time during the course of the disease, and then to the DIPSS Plus, which also incorporates the need for red blood cell transfusions, platelet count o100 109/l and unfavorable karyotype (Table 1).6

PROGNOSISNewer prognostic models have incorporated the DIPSS Plus model. Low-risk disease is dened as the presence of no adverse factors, and has a median survival of 15 years.6 Intermediate-1 risk is the presence of one risk factor and has a median survival of 7 years. Patients with intermediate-2 disease have two or three risk factors and a median survival of 2.9 years. Finally, high-risk patients have four or more adverse factors with a median

survival of only 1.3 years. Thus, these newer prognostic models can aid in selecting the appropriate higher risk patients for transplantation. Recently, an analysis of 884 patients, which included 38% DIPSS Plus patients, reported features associated with a greater than 80% 2-year mortality. These poor prognostic features included monosomal karyotype, inv (3)/i(17q) abnormalities, or any two of the following factors: peripheral blast percentage 49%, white blood count X40 109/l or other

unfavorable karyotype.7 Thus, these modern predictive scores allow selection of patients who are likely to do poorly with conventional treatment.

CHOICE OF TREATMENTAlthough allogeneic hematopoietic stem cell transplantation (HCT) remains the only known curative therapy for myelobrosis, other treatment options must be considered, especially for patients with lower risk disease. These options include observation, erythroid-stimulating agents, hydroxyurea, prednisone, thalidomide or lenalidomide.8,9 Response rates, including improvement in blood counts and splenomegaly, vary but are about 20%.10 Low-dose radiation treatments or splenectomy can also be helpful for painful splenomegaly.11 These treatments may be helpful for palliation of symptoms, but the responses are of short duration, usually less than 1 year.

Table 1. DIPSS Plus

Variable DIPSS (points)

DIPSS Plus (points)

Age 465 years 1 1 Constitutional symptoms 1 1 Hemoglobin o100 g/l 2 1

White blood count 425 109/l 1 1

Circulating blasts 41% 1 1 Platelet count o100 109/l --- 1

Red blood cell transfusion-dependent --- 1 Unfavorable karyotype --- 1

Abbreviation: DIPSS, Dynamic International Prognostic Scoring System.

Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA. Correspondence: Dr K Ballen, Division of Hematology/Oncology, Massachusetts General Hospital, Zero Emerson, Suite 118, Boston, MA 02114, USA.

E-mail: mailto:[email protected]

Web End [email protected]

Received 05 August 2011; revised 13 January 2012; accepted 17 January 2012

Transplant question in myelobrosis K Ballen

2 INVESTIGATIONAL TREATMENTSInvestigational options for the treatment of myelobrosis have blossomed with the discovery of JAK2 kinase inhibitors. The JAK2 inhibitors tested in clinical trial include INCB018424, TG101348 and CEP-701.12 The majority of patients had improvement in constitutional symptoms, and 44% had improvement in spleen size, with major side effects being thrombocytopenia and a cytokine rebound reaction.12 Other drugs under investigation include pomalidomide and the histone deacetylase inhibitors.13

The impact of these investigational agents on the long-term management of myelobrosis is uncertain.

ALLOGENEIC STEM CELL TRANSPLANTATION Myeloablative transplant

Allogeneic transplantation is the only known curative treatment for myelobrosis. Several studies have shown survival rates of 40--60% after allogeneic stem cell transplantation (Table 2). The rst transplants for myelobrosis used myeloablative conditioning, usually total body radiation or busulfan-based treatment. Guardiola et al.14 reported on 55 patients with a median age of 42 years and showed a 5-year overall survival of 47%. Anemia was a predictive factor for poor survival.

The largest study, reported by Ballen et al.15 from the Center for International Blood and Marrow Transplant Research (CIBMTR), analyzed 289 patients with primary myelobrosis. Patients were transplanted between 1989 and 2002 at 118 centers, with a variety of conditioning regimens. Patient and disease characteristics were very heterogeneous, as typical for registry studies. A total of 162 patients received a human leukocyte antigen (HLA)-matched sibling transplant, 101 received a matched unrelated donor (MUD) transplant and 26 received a graft from a non-HLA-matched related donor. The majority of patients received bone marrow as the stem cell source, and 83% received an ablative regimen, likely reecting the time period of the study. The 100-day transplant-related mortality was 18% for the HLA-matched sibling patients and 33% for the MUD patients. Graft failure rate was 9% for the HLA-matched sibling patients and 20% for the MUD patients. Splenomegaly did not impact the graft failure rate. Graft versus host disease (GVHD) grades II--IV occurred in 43% of the sibling patients and 40% of the MUD patients. The overall survival at 5 years was 37% for the sibling patients and 30% for the MUD recipients. Disease-free survival at 5 years was 33% for recipients of an HLA-identical sibling allograft and 27% for recipients of a MUD transplant. Thus, about one out of three patients can be cured of their disease after allogeneic transplant. Positive predictors for survival in this study included an HLA-identical sibling donor, performance status X90% and no peripheral blood blasts.15 Patients who had a poor Karnofsky score, peripheral blood blasts and an unrelated donor had 15% 3-year probability of survival.

Other reports of allogeneic transplant have conrmed the ndings of the CIBMTR study. The Italian group analyzed 100 patients from 26 centers; 48% received a myeloablative

conditioning regimen.16 The risk of graft failure was 13%, and the 1-year transplant-related mortality was 35%. The 5-year overall and disease-free survival rates were 31% and 28%, respectively. Positive predictors for survival included an HLA-matched sibling donor, transplantation after 1995 and a short interval between diagnosis and transplantation.

The French group reported similar results. A total of 147 patients with primary or secondary myelobrosis received an allogeneic stem cell transplant, 31% with a myeloablative regimen.17 Sixty percent of patients received a transplant from an HLA-identical sibling donor. Forty-three percent of patients had acute GVHD, grades II--IV. The 4-year overall survival was 39%, progression-free survival 32% and the non-relapse mortality was 39%. In a multivariate analysis, neither the Lille nor IPSS score predicted survival. Positive predictors for survival included splenectomy, female gender and an HLA-identical sibling donor.

Other studies have conrmed these results. The Seattle group reported on 104 patients with myelobrosis, either primary or after polycythemia vera or essential thrombocythemia.18 The

survival at 7 years was 61%. Use of a targeted busulfan-based chemotherapy regimen, younger age and a lower comorbidity score predicted for better survival. Investigators, including Mittal et al.19, Ditschokowski et al.20, Deeg et al.21, Kerbauy et al.22 and Daly et al.23 have all reported 3-year probabilities of overall survival of 37--58% in small series.

REDUCED-INTENSITY CONDITIONINGBecause of the advanced age of many patients with myelobrosis and hematological malignancies, and the high transplant-related mortality with traditional myeloablative conditioning, the transplant community has pioneered reduced-intensity conditioning (RIC). The RIC regimens use chemotherapy, often udarabine-based, which is more immunosuppressive than myelosuppressive.24--26 Early RIC studies for myelobrosis included the work of Devine et al.27 and Rondelli et al.28. Table 3 outlines the larger studies for myelobrosis. Kroger et al.29 treated 103 patients with primary myelobrosis or myelobrosis post-polycythemia vera or essential thrombocythemia. Patients received a busulfan- and udarabine-based conditioning regimen. A total of 98% of the patients engrafted, and acute GVHD grades II--IV occurred in 27% of the patients. The incidence of relapse at 3 years was 22%, and patients with a low Lille score had a lower incidence of relapse, 14% versus 34%, suggesting patients transplanted earlier in the course of disease fared better. The 5-year event-free survival was 51% and as expected, younger patients and those with a matched donor did better. These results are impressive and mimic the survival seen with a myeloablative preparative regimen.

The Swedish group compared results from 17 patients undergoing myeloablative with 10 patients undergoing reduced intensity transplant for myelobrosis.30 Transplant-related mortality was lower in the reduced intensity arm, 10% versus 30%. With a median follow-up of 55 months, 90% of reduced intensity patients and 55% of the myeloablative patients are alive. However, the

Table 2. Allogeneic stem cell transplantation for myelobrosis

Author N Median age (years) 1-year TRM, % 5-year overall survival, % 5-year progression free-survival, %

Ballen et al.15 289 47 27 (sibling), 43 (unrelated) 37 (sibling), 30 (unrelated) 33 (sibling), 27 (unrelated) Patriarca et al.16 100 49 35 31 28Robin et al.17 147 53 29 (4 years) 39 (4 years) 32 (4 years) Kerbauy et al.22 104 47 27 61 (7 years) ---Deeg et al.21 56 43 35 58 ---

Abbreviation: TRM, transplant-related mortality.

Blood Cancer Journal & 2012 Macmillan Publishers Limited

Transplant question in myelobrosis K Ballen

3

Table 3. Reduced-intensity allogeneic stem cell transplantation for myelobrosis

Author N Median age (years) 1-year TRM, % 5-year overall survival, % 5-year progression-free survival, %

Kroger et al.29 103 53 16 67 51 Merrup et al.30 27 51 10 (RIC), 30 (ablative) 90 (RIC), 55 (ablative) ---Ballen et al.15 60 47 (myeloablative and RIC) 15 --- 39 Bacigalupo et al.37 46 51 24 45 43

Alchalby et al.42 162 57 22 62 46Stewart et al.32 51 54 32 (RIC), 41 (ablative; 3 years) 31 (RIC), 44 (ablative) 24 (RIC), 44 (ablative)

Abbreviations: RIC, reduced-intensity conditioning; TRM, transplant-related mortality.

groups were not randomized. There were no signicant predictors of improved survival.

The CIBMTR study, reported by Ballen et al.15 and described above, included 60 patients who received reduced intensity or non-myeloablative regimens. Transplant-related mortality was 15%, less than for the myeloablative patients, and disease-free survival was comparable at 39%. Snyder et al.31 using tacrolimus and sirolimus for GVHD prophylaxis, reported a low incidence (10%) of acute GVHD grades III--IV and 93% survival. Stewart et al.32 treated 27 patients with a myeloablative and 24 patients with a reduced intensity regimen. There was no difference in non-relapse mortality, overall survival or progression-free survival between the myeloablative and reduced intensity groups. With the use of RIC regimens, patients in their 60s and 70s have been transplanted successfully.33 Predictive factors for survival are difcult to ascertain in the large registry studies that combine both myeloablative and RIC recipients. The RIC regimens have been instrumental in expanding transplant eligibility; these regimens reduce the transplant-related mortality compared with high-intensity regimens, but without randomized studies, the exact improvement in survival is difcult to determine.

ALTERNATIVE DONOR TRANSPLANTOnly 30% of patients have a matched sibling donor and it is often difcult for African Americans and other minorities to nd MUDs. Alternative stem cell graft sources for these patients include umbilical cord blood, a mismatched unrelated donor, or a mismatched family member (haploidentical) transplant. These graft sources have never been compared in a randomized fashion, and the optimal graft source for patients without a fully matched related donor or MUD is uncertain.34 Umbilical cord blood transplantation is a useful alternative stem cell source for patients without matched donors.35 Because of the delayed engraftment routinely seen after cord blood transplant, transplant physicians may have been reluctant to extend cord blood transplantation to patients with myelobrosis. The recent report of Takagi et al.36

suggest that successful engraftment can be achieved after reduced-intensity umbilical cord blood transplantation for myelobrosis. Fourteen patients classied as myelobrosis, including several that had transformed to acute myelogeneous leukemia, underwent cord blood transplant with an RIC regimen. In all, 13 patients engrafted, and the overall survival was 29% at 4 years.

PREDICTORS FOR SURVIVALSelection of the appropriate patients for transplant and the appropriate timing of transplant have been difcult, given the early risk associated with transplant, even a reduced intensity transplant. Predictive factors studied have included age, graft source, performance status, comorbidity score, splenomegaly, Dupriez score or IPSS score. The CIBMTR study reported by Ballen et al.15 found that an HLA-identical sibling donor, performance status X90% and no peripheral blood blasts predicted for better

survival. Recently, Bacigalupo et al.37 have formulated a predictive score for survival. Forty-six patients underwent a reduced intensity transplant for primary myelobrosis with a thiotepa-based regimen, either thiotepa and cyclophosphamide, or thiotepa, cyclophosphamide and melphalan. In a multivariate analysis, independent factors for poor survival were 420 red blood cell transfusions, spleen size 422 cm and an alternative donor. Two or more risk factors were considered high risk, and these high-risk patients had a 5-year survival of 8%, compared with 77% for the low-risk patients with 0 or 1 risk factor. These results suggest that certain high-risk patients may not benet from allogeneic stem cell transplant. The predictive score maintained its predictive value even when correcting for patient age, Dupriez, or IPSS score.

Scott et al.38 presented a preliminary analysis of predictive factors for survival after allogeneic transplantation for myelobrosis. The authors retrospectively studied 169 recipients of allogeneic HCT in Seattle. The International Working Group score, based on age, constitutional symptoms, anemia, leukocytosis and circulating peripheral blasts, was highly predictive for survival after HCT. At 1 year, survival was 40% in the high-risk group and 80% in the low-risk group.

Splenomegaly and splenectomyThe appropriate management of the spleen pre-HCT remains controversial. Ciurea et al.39 showed prolonged neutrophil and platelet recovery in patients with massive splenomegaly, but no effect on survival. Preliminary data from the CIBMTR in a broader population found that splenectomy facilitates engraftment, but had no effect on transplant-related mortality.40 Recently, post-transplant splenectomy has been studied as a way to manage delayed engraftment in patients with splenomegaly and myelobrosis.41

Markers of minimal residual diseaseThe role of JAK2 V617F status after transplant is controversial.

A study of 162 patients treated with RIC showed a reduced survival in patients with the JAK2 wild type.42 Patients who cleared the JAK2 mutation 6 months after transplant had a lower risk of relapse (5% versus 35%, P 0.03). The reappearance of the

JAK2 gene mutation after transplant was associated with the presence of mixed chimerism and relapse; thus, JAK2 mutation serves as a marker of minimal residual disease.43 The JAK2

kinase inhibitor ruxolitinib has recently been approved by the United States Food and Drug Association and is commercially available. The role of the JAK2 kinase inhibitors as part of a transplantation strategy is unclear; these drugs might be helpful for disease reduction pre-HCT or as maintenance therapy post-HCT.

Treatment failureThe options for patients that relapse after HCT are limited.

Stewart et al.32 showed a trend toward a higher rate of relapse in

& 2012 Macmillan Publishers Limited

Blood Cancer Journal

Transplant question in myelobrosis K Ballen

4 patients who received RIC regimens compared retrospectively with patients who received myeloablative conditioning. Donor lymphocyte infusion has been utilized for post-HCT relapse, but it is not clear if there is a strong graft versus myelobrosis effect.32

CHOOSING BETWEEN TRANSPLANT AND NON-TRANSPLANT THERAPY

Allogeneic transplant remains the only curative therapy for myelobrosis, but the transplant-related mortality remains high, at 15--30%, and there can be signicant morbidity for patients with chronic GVHD. Thus, the selection of patients for transplant is crucial. Some centers will transplant only those patients whose median survival is less than 5 years without transplant, such as those patients with intermediate-2 and high-risk disease.44

Another approach would be to exclude patients with high-risk features of splenomegaly 422 cm, 420 transfusions and alternative donor as dened by Bacigalupo et al.37; these patients have less than a 10% survival after HCT.

For low-risk patients, a more aggressive approach is to monitor these patients and to perform transplant early in the disease if there are any signs of progression, such as anemia, increased lactate dehydrogenase or constitutional symptoms.45

How to manage the transplant question in myelobrosisAt Massachusetts General Hospital, we perform allogeneic transplants up to age 75. In general, patients over age 60 years or with signicant comorbid disease will receive a reduced intensity regimen, usually busulfan and udarabine. Younger patients receive a myeloablative regimen with busulfan and cyclophosphamide. Patients without a matched sibling donor proceed to unrelated donor search. If an HLA 10/10 allele-matched donor is identied, patients will receive an unrelated transplant. Patients without matched related donor or fully MUD receive double cord blood transplant at our center.35 Patients must have a performance status of 0, 1, 2 and adequate organ function to proceed to transplant. An algorithm for transplantation is shown in Figure 1.

As many patients with myelobrosis enjoy prolonged survival, we select those patients whose survival is likely to be less than 5 years with conventional therapy. Patients with monosomal karyotype have a median survival of 6 months and should be transplanted promptly.46

Patient with low-risk disease by the DIPSS criteria have a median survival of 15 years and should not be considered for transplant, given the morbidity and mortality of allogeneic transplant.10 Patients with intermediate-1 disease have a median survival of 6 years; these patients are considered for transplant and HLA typing performed. However, these patients symptoms can often be managed by hydroxyurea or low-dose splenic radiation, and it is reasonable to try these measures rst before proceeding to transplant. However, most patients with intermediate-1 disease will die of myelobrosis or its complications, and should be considered as potential transplant candidates.

Patients with intermediate-2 have a median survival of 2.9 years, and patients with high-risk disease have a median survival of 1.3 years. These patients are considered for immediate transplant as soon as a suitable donor is identied. Patients who have transformed to acute leukemia receive induction chemotherapy before transplantation. Patients with massive splenomegaly may undergo low-dose splenic radiation before transplant.

Patients who are likely to have o10% long-term survival after transplant are excluded from transplant. These patients may have the risk factors mentioned, including massively enlarged spleen and a signicant transfusion requirement. Patients with poor performance status and signicant comorbid conditions may not be transplant candidates.

CONCLUSIONTreatment for myelobrosis has evolved with a better understanding of the prognostic factors for survival. Investigational agents such as pomalidomide are currently in clinical trial, and a JAK2 kinase inhibitor is now approved for use in the United States. Allogeneic transplant remains the only known curative therapy for this disease. The advent of RIC has extended the upper age limit of HCT into the 70s. Alternative donor transplantation, including umbilical cord blood transplantation, has provided a larger number of patients, particularly minority patients, with the option for transplant. Over the next 5 years, reduction of transplant-related mortality and optimal patient selection will ensure continued progress in this eld.

CONFLICT OF INTEREST

The author declares no conict of interest.

REFERENCES

1 Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al.

The 2008 revision of the World Health Organization (WHO) classication of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937 -- 951.2 Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008; 22: 1299 -- 1307.3 Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelobrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092 -- 1097.4 Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013 -- 1018.5 Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelobrosis based on a study of the International Working Group for Myelobrosis Research and Treatment. Blood 2009; 113: 2895 -- 2901.6 Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSS-Plus: a rened Dynamic International Prognostic Scoring System (DIPSS) for primary myelobrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392 -- 397.

Primary Myelofibrosis

Low Risk

Intermediate 1

Intermediate 2

High Risk

No Transplant

Consider For Transplant HLA type Try Conventional Therapy First

Immediate Transplant if Transplant Eligible

Immediate Transplant if

Transplant Eligible

Figure 1. Selection strategy for transplantation in primary myelobrosis.

Blood Cancer Journal & 2012 Macmillan Publishers Limited

Transplant question in myelobrosis K Ballen

5

7 Tefferi A, Jimma T, Gangat N, Vaidya R, Begna KH, Hanson CA et al. Predictors of greater than 80% 2-year mortality in primary myelobrosis: a Mayo Clinic study of 884 karyotypically annotated patients. Blood 2011; 118: 4595 -- 4598.

8 Cervantes F, Alvarez-Laran A, Hernandez-Boluda JC, Sureda A, Torrebadell M, Montserrat E. Erythropoietin treatment of the anemia of myelobrosis with myeloid metaplasia: results in 20 patients and review of the literature. Brit J Hematol 2004; 127: 399 -- 403.

9 Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL et al. Lenalidomide therapy in myelobrosis with myeloid metaplasia. Blood 2006; 108: 1158 -- 1164.

10 Tefferi A. How I treat myelobrosis. Blood 2011; 117: 3494 -- 3504.11 Tefferi A, Mesa RA, Nogomey DM, Schroeder G, Silverstein MN. Splenectomy in myelobrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000; 95: 2226 -- 2233.12 Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. Safety and efcacy of INCB018424, a JAK 1 and JAK 2 inhibitor, in myelobrosis. N Engl J Med 2010; 363: 1117 -- 1127.13 Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF et al. A phase 2 trial of low-dose pomalidomide in myelobrosis with anemia. Leukemia 2011; 25: 301 -- 304.14 Guardiola P, Anderson JE, Bandini G, Cervantes F, Funde V, Arcese W et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppos Italiano per il Trapianto Del Midollod Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999; 93: 2831 -- 2838.15 Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ et al. Outcome of transplantation for myelobrosis. Biol Blood Marrow Transplant 2010; 16: 358 -- 367.16 Patriarca F, Bacigalupo A, Sperotto A, Isola M, Soldano F, Bruno B et al. Allogeneic hematopoietic stem cell transplantation in myelobrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Hematologica 2008; 93: 1514 -- 1522.17 Robin M, Tabrizi R, Mohty M, Furst S, Michallet M, Bay JO et al. Allogeneic hematopoeitic stem cell transplantation for myelobrosis: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Brit J Hematol 2010; 10: 1 -- 9.18 Zang DY, Deeg HJ. Allogeneic hematopoietic cell transplantation for patients with myelobrosis. Curr Opin Hematol 2009; 15: 140 -- 146.19 Mittal P, Saliba RM, Giralt SA, Shahjahan M, Cohen AI, Karandish S et al. Allogeneic transplantation: a therapeutic option for myelobrosis, chronic myelomonocytic leukemia, and Philadelphia negative/bcr-abl negative chronic myelogeneous leukemia. Bone Marrow Transplant 2004; 3: 1005 -- 1009.20 Ditschkowski M, Beelen DW, Trenschel R, Koldehoff M, Elmaagacli AH. Outcome of allogeneic stem cell transplantation in patients with myelobrosis. Bone Marrow Transplant 2004; 34: 807 -- 813.21 Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C et al. Allogeneic hematopoietic transplantation for myelobrosis. Blood 2003; 102: 3912 -- 3918.22 Kerbauy DM, Gooley TM, Sale GE, Flowers ME, Doney KC, Georges GE et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelobrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 2007; 13: 355 -- 365.23 Daly A, Song K, Nevill T, Nantel S, Toze C, Hogge D et al. Stem cell transplantation for myelobrosis: a report from two Canadian centers. Bone Marrow Transplant 2003; 32: 35 -- 40.24 Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756 -- 763.25 Dey BR, McAfee S, Sackstein R, Colby C, Saidman S, Weymouth D et al. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 604 -- 612.26 Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631 -- 637.27 Devine SM, Hoffman R, Verma A, Shah R, Bradlow BA, Stock W et al. Allogeneic blood cell transplantation following reduced intensity conditioning is effective

therapy for older patients with myelobrosis with myeloid metaplasia. Blood 2002; 99: 2255 -- 2258.28 Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate-or high-risk patients with myelobrosis with myeloid metaplasia. Blood 2005; 105: 4115 -- 4119.29 Kroger N, Holler E, Kobbe G, Bornhauser M, Schwedtfeger R, Baurmann H et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelobrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 5264 -- 5270.30 Merrup M, Lazarevic V, Nahi H, Andreasson B, Malm C, Nilsson L et al. Different outcome of allogeneic transplantation in myelobrosis using conventional or reduced-intensity conditioning regimens. Brit J Hematol 2006; 135: 367 -- 373.31 Snyder DS, Palmer J, Gaal K, Pullarkat V, Sahebi F, Cohen S et al. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment for myelobrosis. Biol Blood Marrow Transplant 2010; 16: 281 -- 286.32 Stewart WA, Pearce R, Kirkland KE, Bloor A, Thomson K, Apperley J et al. The role of allogeneic SCT in primary myelobrosis: a British Society for Blood and Marrow Transplantation Study. Bone Marrow Transplant 2010; 45: 1587 -- 1593.33 Samuelson S, Sandmaier BM, Heslop HE, Popat U, Carrum G, Champlin RE et al. Allogeneic hematopoietic cell transplantation for myelobrosis in 30 patients 60 -- 78 years of age. Brit J Hematol 2011; 153: 76 -- 82.34 Ballen KK, Spitzer TR. The great debate: haploidentical or cord blood transplant. Bone Marrow Transplant 2011; 46: 323 -- 329.35 Ballen KK, Spitzer TR, Yeap BY, McAfee S, Dey B, Attar E et al. Double unrelated reduced intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007; 13: 82 -- 89.36 Takagi S, Ota Y, Uchida N, Takahashi K, Ishiwata K, Tsuji M et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelobrosis. Blood 2010; 116: 649 -- 652.37 Bacigalupo A, Soraru M, Dominietto A, Pozzi S, Geroldi S, Van Lint MT et al. Allogeneic hematopoietic SCT for patients with primary myelobrosis: a predictive transplant score based on transfusion requirement, spleen size, and donor type. Bone Marrow Transplant 2010; 45: 458 -- 463.38 Scott BL, Gooley TA, Linenberger ML, Sandmaier BM, Myerson D, Chauncey T et al. International Working Group scores predict post-transplant outcomes in patients with myelobrosis. Blood 2010; 116: 965a (abstract).39 Ciurea SO, Sadegi B, Wilbur A, Alagiozian-Angelova V, Gaitonade S, Dobogai LC et al. Effects of extensive splenomegaly in patients with myelobrosis undergoing a reduced intensity allogeneic stem cell transplantation. Brit J Hematol 2008; 141: 80 -- 83.40 Akpek G, Pasquini MC, Agovi MA, Logan B, Cooke KR, Maziarz RT et al. Spleen status and engraftment after allogeneic hematopoietic stem cell transplantation. Blood 2010; 116: 3486a.41 Robin M, Esperous H, Peffault R, Petropoulou AD, Xhaard A, Ribauad P et al. Splenectomy after allogeneic hematopoietic stem cell transplantation in patients with primary myelobrosis. Brit J Hematol 2010; 150: 721 -- 724.42 Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelobrosis. Blood 2010; 116: 3572 -- 3581.43 Steckel NK, Koldehoff M, Ditschkowski M, Beelen DW, Elmaagacli AH. Use of the activating gene mutation of the tyrosine kinase JAK2 as a minimal disease marker in patients with myelobrosis and myeloid metaplasia after allogeneic stem cell transplantation. Transplantation 2007; 83: 1518 -- 1520.44 Tefferi A. Allogeneic hematopoietic cell transplantation versus drugs in myelobrosis: the risk-benet balancing act. Bone Marrow Transplant 2010; 45: 419 -- 421.45 Kroger N, Mesa RA. Choosing between stem cell therapy and drugs in myelobrosis. Leukemia 2008; 22: 474 -- 486.46 Vaidya R, Caramazza C, Begna KH, Gangat N, VanDyke DL, Hanson CA et al. Monosomal karyotype in primary myelobrosis is detrimental to both overall and leukemia-free survival. Blood 2011; 117: 5612 -- 5615.

This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/

& 2012 Macmillan Publishers Limited

Blood Cancer Journal